Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

<p>FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) [p= 0.058] and eGFR chronic slope (1.1 mL/min/1.73m2 per year) [p=0.037]. Patients treated with FILSPARI over two years exhibited one of the slowest annual rates of kidney function decline seen in a clinical trial of IgAN patients (-2.7 [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/travere-therapeutics-announces-confirmatory-data-from-the-phase-3-protect-study-of-filspari-demonstrating-long-term-kidney-function-preservation-in-iga-nephropathy-narrowly-missing-egfr-total-s/">Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>